Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Krka Group
Alongside discussing the firm’s preliminary financial results for 2021, Krka management explained how the company planned to make further inroads in China in 2022 and return to its 2020 revenue baseline in West Europe, following a dip last year.
Slovenian firm Krka wishes to strengthen and optimize its vertically integrated business model over the next five years, just one of many goals just published by the company under a new business plan to 2026.
Having picked up five prescription marketing authorization approvals in the first half of 2021, Slovenian generics giant Krka will be hoping to build on stagnant prescription pharmaceuticals reported in preliminary financial results.
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Krka DD, Krka d.d., Krka Pharmaceuticals